YKST06

YKST06 is a preclinical-stage bispecific antibody being developed by Excyte Biopharma for the treatment of metastatic colorectal cancer (mCRC). As part of Excyte Biopharma's oncology pipeline, which focuses on multi-specific antibody platforms, YKST06 is designed to address advanced solid tumors. While its specific molecular targets have not been publicly disclosed in available pipeline documentation (where the indication 'mCRC' was listed in the target field), it belongs to a class of therapeutics typically engineered to bridge immune effector cells with tumor cells or to inhibit multiple signaling pathways simultaneously. The program is currently in the early stages of preclinical development.